{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:35:44Z","timestamp":1793208944256,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,28]]},"DOI":"10.1093\/ejhf\/xuag220","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:39:29Z","timestamp":1784288369000},"page":"804-806","source":"Crossref","is-referenced-by-count":0,"title":["From access to action in transthyretin amyloid cardiomyopathy: are we missing opportunities for therapy optimization?"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-2857","authenticated-orcid":false,"given":"Daniela","family":"Tomasoni","sequence":"first","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , P.le Spedali Civili 1, Brescia 25123 ,","place":["Italy"]},{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna , Pisa ,","place":["Italy"]},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026102813141735600_xuag220-B1","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1002\/ejhf.70030","article-title":"High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: the CAPTURE study","volume":"27","author":"Aimo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102813141735600_xuag220-B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2026.102723","article-title":"Cardiac amyloidosis: disease overview and novel pathophysiologic insights","volume":"59S","author":"Tersalvi","year":"2026","journal-title":"J Nucl Cardiol"},{"key":"2026102813141735600_xuag220-B3","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/ejhf.3455","article-title":"The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis","volume":"27","author":"Bonfioli","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102813141735600_xuag220-B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/eurheartj\/ehaf710","article-title":"Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association","volume":"47","author":"Garcia-Pavia","year":"2026","journal-title":"Eur Heart J"},{"key":"2026102813141735600_xuag220-B5","doi-asserted-by":"publisher","DOI":"10.1093\/ejhf\/xuag141","article-title":"Outpatient clinic visits before and after hospitalizations for heart failure with and without transthyretin amyloid cardiomyopathy","author":"Haywood","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026102813141735600_xuag220-B6","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/EJHF.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026102813141735600_xuag220-B7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","article-title":"Sex differences in transthyretin cardiac amyloidosis","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"},{"key":"2026102813141735600_xuag220-B8","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/ejhf.70071","article-title":"Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis","volume":"27","author":"Porcari","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102813141735600_xuag220-B9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.cardfail.2026.02.041","article-title":"The burden of amyloid transthyretin cardiomyopathy in heart failure with preserved ejection fraction: looking beyond the tip of the iceberg","volume":"32","author":"Aimo","year":"2026","journal-title":"J Card Fail"},{"key":"2026102813141735600_xuag220-B10","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102813141735600_xuag220-B11","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026102813141735600_xuag220-B12","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102813141735600_xuag220-B13","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1002\/ehf2.15408","article-title":"SGLT2 inhibitors for the prevention and treatment of heart failure: a scientific statement of the HFA and the HFAI","volume":"12","author":"Metra","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026102813141735600_xuag220-B14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2874","article-title":"Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026102813141735600_xuag220-B15","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102813141735600_xuag220-B16","doi-asserted-by":"publisher","first-page":"102549","DOI":"10.1016\/j.jchf.2025.102549","article-title":"Outcome and disease progression in NYHA functional class I and II patients with wild-type transthyretin cardiomyopathy treated with tafamidis","volume":"13","author":"Sinigiani","year":"2025","journal-title":"JACC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag220\/69522124\/xuag220.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/804\/69522124\/xuag220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/804\/69522124\/xuag220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:14:24Z","timestamp":1793207664000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/4\/804\/8737736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,20]]},"published-print":{"date-parts":[[2026,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag220","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]}}}